PharmiWeb

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and …

FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against ...
PharmiWeb

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation ...
PharmiWeb

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive B…

ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...
PharmiWeb

Lithium Royalty Corp. Congratulates Power Metals on Offtake Agreement with Albemarle; Power Metals Reaffirms 2026 Production Target

Power Metals entered into a cesium concentrate offtake agreement with Albemarle Corporation, a US$16 billion global critical ...
PharmiWeb

Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for ...
PharmiWeb

Insights Into the Booming Peptide Cancer Vaccines Market 2025-2031: Key Trends & Opportunities in Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Other Applications ...

The "Peptide Cancer Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031" has been added to ResearchAndMarkets.com's offering.The global peptide cancer vaccine market is expected ...
PharmiWeb

Zealthy Review 2026: How Zealthy Compares to FitRx and RoenRx for Weight Loss & GLP-1 Care

LOS ANGELES, CA / ACCESS Newswire / December 12, 2025 / The landscape of weight management has undergone a seismic shift. Zealthy is one of the fastest-growing telehealth weight-loss platforms in the ...
PharmiWeb

Expanded PTFE Market Report 2025: Trends, Forecast and Competitive Analysis to 2031 with Profiles on The Chemours Company, 3M Company, Saint-Gobain, Nitto Denko, Arkema ...

Trends, Forecast and Competitive Analysis to 2031" has been added to ResearchAndMarkets.com's offering.The global expanded PTFE market is expected to grow with a CAGR of 6.1% from 2025 to 2031. The ...
PharmiWeb

Prothena Announces Board of Directors Update

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced ...
PharmiWeb

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, ...
PharmiWeb

VSee Health, Inc. Announces Postponement of Annual Meeting of Stockholders Until December 30, 2025

SAN JOSE, CALIFORNIA / ACCESS Newswire / December 12, 2025 / VSee Health, Inc. (NASDAQ:VSEE) a leader in innovative telemedicine solutions, today announced that it anticipates that it will not have a ...
PharmiWeb

Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the ...